%0 Journal Article
%T Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors.
%A Yi JR
%A Zhong NN
%A Lin H
%A Liu XH
%A Yang Y
%A Liu B
%A Man QW
%J J Stomatol Oral Maxillofac Surg
%V 125
%N 3
%D 2024 Jun 29
%M 38556167
%F 2.48
%R 10.1016/j.jormas.2024.101846
%X Oral and maxillofacial tumors pose a significant clinical challenge due to their tendency to recur, despite advancements in surgical removal techniques. The jaw's intricate structure further complicates treatments and affects patient quality of life. Consequently, emphasis has shifted towards pharmacological interventions, to potentially reduce invasive surgical procedures. One promising approach targets BRAF mutations, specifically the common V600E mutation. BRAF, a critical protein kinase, regulates cell growth and differentiation via the RAS-RAF-MEK-ERK-MAP kinase pathway. A specific nucleotide change at position 1799, swapping Thymine (T) for Adenine (A), results in the V600E mutation, causing unchecked cell growth. This mutation is common in certain oral and maxillofacial tumors like ameloblastoma. A recent neoadjuvant therapy targeting BRAF, involving the use of dabrafenib and trametinib, has showcased a promising, safe, and effective strategy for organ preservation in the treatment of mandibular ameloblastoma. This convergence of molecular insights and targeted therapies holds the key to managing BRAF-mutated oral and maxillofacial tumors effectively, promising improved patient outcomes.